Kyle Diamantas leads as acting FDA commissioner following Marty Makary’s May 2026 departure, bolstered by his prior role overseeing the Human Foods Program and reports of building internal trust during the transition. The field remains competitive because other candidates—including former commissioner Stephen Hahn, ex-acting commissioner Brett Giroir, former principal deputy Sara Brenner, and deputy commissioner Grace Graham—bring established FDA or HHS experience that aligns with administration priorities on regulatory reform and agency leadership. Trader positioning reflects the absence of a confirmed nominee announcement months into the process, the requirement for Senate confirmation, and the administration’s review of finalists. The substantial share assigned to no announcement by year-end captures uncertainty over timing and whether an insider or external pick will emerge before the end of 2026.